- Home
- JRS vs FENC Comparison
JRS vs FENC Comparison
Compare JRS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
SELL
Current Price
$10.11
Company Overview
Basic Information| Metric | JRS | FENC |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.8M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | JRS | FENC |
|---|---|---|
| Price | $8.67 | $10.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 86.1K | ★ 193.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,015.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $5.65 |
| 52 Week High | $8.75 | $11.31 |
Technical Indicators
Market Signals| Indicator | JRS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 48.70 |
| Support Level | $8.05 | $10.04 |
| Resistance Level | $8.75 | $10.45 |
| Average True Range (ATR) | 0.11 | 0.56 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 71.43 | 20.07 |
Price Performance
Historical Comparison JRS
FENC
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.